Progress of research on NELL-1 in membranous nephropathy

doi:10.3877/cma.j.issn.2095-3216.2022.05.009

Abstract

Abstract:

Membrane nephropathy (MN) is a common glomerular disease. Its pathogenesis is that as the antibody combines its podocyte antigen, immune complexes deposit in the glomerular basement membrane, which in turn leads to complement activation, podocyte damage, and structural changes in the glomerular basement membrane. In recent years, it has been found that neural epidermal growth factor-like 1 protein (NELL-1) is a new target antigen of MN after the finding of the main target antigen of MN, M-type phospholipase A2 receptor (PLA2R). NELL-1 is closely related to segmental MN and tumors. This review focused on the new progress of research on NELL-1 in its structure, expression, etc.

Key words: Neural epidermal growth factor-like 1 protein, Primary membranous nephropathy, M-type phospholipase A2 receptor, Segmental membranous nephropathy, Tumor

Yangyang Xin, Xingzhi Wang. Progress of research on NELL-1 in membranous nephropathy[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2022, 11(05): 290-293.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2022.05.009

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2022/V11/I05/290

Figures/Tables 1

References 33

[1]	Couser WG. Primary membranous nephropathy [J]. Clin J Am Soc Nephrol, 2017, 12(6): 983-997.
[2]	Tomas NM, Huber TB, Hoxha E. Perspectives in membranous nephropathy [J]. Cell Tissue Res, 2021, 385(2): 405-422.
[3]	Ahmad SB, Appel GB. Antigens, antibodies, and membranous nephropathy: a decade of progress [J]. Kidney Int, 2020, 97(1): 29-31.
[4]	Matsuhashi S, Noji S, Koyama E, et al. New gene, nel, encoding a M(r) 93 K protein with EGF-like repeats is strongly expressed in neural tissues of early stage chick embryos [J]. Dev Dyn, 1995, 203(2): 212-222.
[5]	Watanabe TK, Katagiri T, Suzuki M, et al. Cloning and characterization of two novel human cDNAs (NELL1 and NELL2) encoding proteins with six EGF-like repeats[J]. Genomics, 1996, 38(3): 273-276.
[6]	Li C, Zhang X, Zheng Z, et al. Nell-1 is a key functional modulator in osteochondrogenesis and beyond [J]. J Dent Res, 2019, 98(13): 1458-1468.
[7]	Sethi S. New 'antigens’ in membranous nephropathy [J]. J Am Soc Nephrol, 2021, 32(2): 268-278.
[8]	Nakamura R, Oyama T, Tajiri R, et al. Expression and regulatory effects on cancer cell behavior of NELL1 and NELL2 in human renal cell carcinoma [J]. Cancer Sci, 2015, 106(5): 656-664.
[9]	Debiec H, Nauta J, Coulet F, et al. Role of truncating mutations in MME gene in fetomaternal alloimmunisation and antenatal glomerulopathies [J]. Lancet, 2004, 364(9441): 1252-1259.
[10]	Beck LH, Bonegio RGB, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy [J]. N Engl J Med, 2009, 361(1): 11-21.
[11]	Tomas NM, Beck LH, Meyer-Schwesinger C, et al. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy [J]. N Engl J Med, 2014, 371(24): 2277-2287.
[12]	Zaghrini C, Seitz-Polski B, Justino J, et al. Novel ELISA for thrombospondin type 1 domain-containing 7A autoantibodies in membranous nephropathy [J]. Kidney Int, 2019, 95(3): 666-679.
[13]	Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases [J]. Kidney Int, 2021, 100(4S): S1-S276.
[14]	Berchtold L, Zanetta G, Dahan K, et al. Efficacy and safety of rituximab in hepatitis B virus-associated PLA2R-positive membranous nephropathy [J]. Kidney Int Rep, 2018, 3(2): 486-491.
[15]	Thet Z, Lam AK, Ranganathan D, et al. Critical evaluation of cancer risks in glomerular disease [J]. Transl Oncol, 2022, 19: 101376.
[16]	Ronco P, Debiec H. Membranous nephropathy: current understanding of various causes in light of new target antigens [J]. Curr Opin Nephrol Hypertens, 2021, 30(3): 287-293.
[17]	Ronco P, Plaisier E, Debiec H. Advances in membranous nephropathy [J]. J Clin Med, 2021, 10(4): 607.
[18]	Sethi S, Madden BJ, Debiec H, et al. Exostosin 1/exostosin 2-associated membranous nephropathy [J]. J Am Soc Nephrol, 2019, 30(6): 1123-1136.
[19]	Sethi S, Debiec H, Madden B, et al. Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy [J]. Kidney Int, 2020, 97(1): 163-174.
[20]	Sethi S, Debiec H, Madden B, et al. Semaphorin 3B-associated membranous nephropathy is a distinct type of disease predominantly present in pediatric patients [J]. Kidney Int, 2020, 98(5): 1253-1264.
[21]	Caza TN, Hassen SI, Kuperman M, et al. Neural cell adhesion molecule 1 is a novel autoantigen in membranous lupus nephritis [J]. Kidney Int, 2021, 100(1): 171-181.
[22]	Wang G, Sun L, Dong H, et al. Neural epidermal growth factor-like 1 protein-positive membranous nephropathy in Chinese patients [J]. Clin J Am Soc Nephrol, 2021, 16(5): 727-735.
[23]	Kudose S, Santoriello D, Debiec H, et al. The clinicopathologic spectrum of segmental membranous glomerulopathy [J]. Kidney Int, 2021, 99(1): 247-255.
[24]	Zhang D, Zhang C, Bian F, et al. Clinicopathological features in membranous nephropathy with cancer: a retrospective single-center study and literature review [J]. Int J Biol Markers, 2019, 34(4): 406-413.
[25]	Beck LH. Membranous nephropathy and malignancy [J]. Semin Nephrol, 2010, 30(6): 635-644.
[26]	Birkeland SA, Storm HH. Glomerulonephritis and malignancy: a population-based analysis [J]. Kidney Int, 2003, 63(2): 716-721.
[27]	Caza TN, Hassen SI, Dvanajscak Z, et al. NELL1 is a target antigen in malignancy-associated membranous nephropathy [J]. Kidney Int, 2021, 99(4): 967-976.
[28]	Plaisier E, Ronco P. Screening for cancer in patients with glomerular diseases [J]. Clin J Am Soc Nephrol, 2020, 15(6): 886-888.
[29]	Kun E, Tsang YTM, Ng CW, et al. MEK inhibitor resistance mechanisms and recent developments in combination trials [J]. Cancer Treat Rev, 2021, 92: 102137.
[30]	Caspi M, Wittenstein A, Kazelnik M，et al. Therapeutic targeting of the oncogenic Wnt signaling pathway for treating colorectal cancer and other colonic disorders [J]. Adv Drug Deliv Rev, 2021, 169: 118-136.
[31]	Sethi S, Madden B, Debiec H, et al. Protocadherin 7-associated membranous nephropathy [J]. J Am Soc Nephrol, 2021, 32(5): 1249-1261.
[32]	Al-Rabadi LF, Caza T, Trivin-Avillach C, et al. Serine protease HTRA1 as a novel target antigen in primary membranous nephropathy [J]. J Am Soc Nephrol, 2021, 32(7): 1666-1681.
[33]	Stefan G, Stancu S, Zugravu A, et al. Negative anti-phospholipase A2 receptor antibody status at three months predicts remission in primary membranous nephropathy [J]. Renal failure, 2022, 44(1): 258-268.

时间	抗原类型	占比	分子量(kDa)	IgG亚类	临床特点	参考文献
2009年	PLA2R	70%~80%	185	IgG4	表现为IMN	[10]
2014年	THSD7A	1%~5%	250	IgG4	表现为IMN，少部分与恶性肿瘤有关	[11]
2019年	EXT1/2	未测定	86/82	IgG1	与自身免疫性疾病相关，尤其SLE	[18]
2020年	NELL-1	5%~10%	90	IgG1	表现为IMN，与恶性肿瘤相关	[19]
2020年	Sema3B	1%~3%	81	IgG1	儿童MN第一抗原	[20]
2021年	PCDH7	1.6%~2%	116	IgG4，IgG1	老年男性，易自发缓解	[30]
2021年	HTRA1	1%~2%	51	IgG4	老年患者	[31]
2021年	NCAM-1	未测定	120	IgG1	多为女性，与SLE密切相关	[21]
2022年	NTNG1	未测定	50	IgG4	主要表现为IMN	[32]

时间	抗原类型	占比	分子量(kDa)	IgG亚类	临床特点	参考文献
2009年	PLA2R	70%~80%	185	IgG4	表现为IMN	[10]
2014年	THSD7A	1%~5%	250	IgG4	表现为IMN，少部分与恶性肿瘤有关	[11]
2019年	EXT1/2	未测定	86/82	IgG1	与自身免疫性疾病相关，尤其SLE	[18]
2020年	NELL-1	5%~10%	90	IgG1	表现为IMN，与恶性肿瘤相关	[19]
2020年	Sema3B	1%~3%	81	IgG1	儿童MN第一抗原	[20]
2021年	PCDH7	1.6%~2%	116	IgG4，IgG1	老年男性，易自发缓解	[30]
2021年	HTRA1	1%~2%	51	IgG4	老年患者	[31]
2021年	NCAM-1	未测定	120	IgG1	多为女性，与SLE密切相关	[21]
2022年	NTNG1	未测定	50	IgG4	主要表现为IMN	[32]

Please choose a citation manager

Content to export